Law360 (March 25, 2019, 10:22 PM EDT) -- Myriad Genetics Inc. and its directors on Monday shook a proposed securities class action alleging a fraudulent billing of Medicare after a Utah federal judge ruled the suing investor failed to plead that the company's billing was illegal or even an outlier in the industry.
U.S. District Judge Dale A. Kimball said lead plaintiff Matthew Kessman's claims that the molecular diagnostics company misled investors about its compliance with federal law regarding billing for cancer screenings hinge, and now falter, on "one critical assumption — that Myriad's billing practices were illegal."
Given that the Center for Medicare and Medicaid Services' guidelines do not prohibit the...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!